5-alpha reductase inhibitors use in prostatic disease and beyond
Translational Andrology and Urology · 2023-03 · 12 (3) · 487-496
DOI: 10.21037/tau-22-690 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Translational Andrology and Urology, 2023-03. Verfasst von Bodie Chislett und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Austin Health, Heidelberg, Melbourne, VIC, Australia. Die Arbeit wurde bisher 62-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Austin Health, Heidelberg, Melbourne, VIC, Australia.
- Young Urology Researchers Organisation (YURO), Melbourne, VIC, Australia.
- Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Urology, Princess Alexandra Hospital, University of Queensland, Brisbane, QLD, Australia.
Förderung
- NCI NIH HHS
Zitieren
APA
Chislett, B., Chen, D., Perera, M. L., Chung, E., Bolton, D., & Qu, L. G. (2023). 5-alpha reductase inhibitors use in prostatic disease and beyond. Translational Andrology and Urology, 12(3), 487-496. https://doi.org/10.21037/tau-22-690
Vancouver
Chislett B, Chen D, Perera ML, Chung E, Bolton D, Qu LG. 5-alpha reductase inhibitors use in prostatic disease and beyond. Translational Andrology and Urology. 2023;12(3):487-496. doi:10.21037/tau-22-690
BibTeX
@article{Chislett2023,
author = {Chislett, Bodie and Chen, David and Perera, Marlon L and Chung, Eric and Bolton, Damien and Qu, Liang G},
title = {5-alpha reductase inhibitors use in prostatic disease and beyond},
journal = {Translational Andrology and Urology},
year = {2023},
volume = {12},
number = {3},
pages = {487--496},
doi = {10.21037/tau-22-690}
}
EUVIMED